King's first UK Centre of Excellence for pharmaceutical medicine training
Posted on 06/02/2012
King’s College London has been accredited as the first UK Centre of Excellence for pharmaceutical medicine training by the Innovative Medicines Initiative Pharmaceutical Medicines Training Programme (PharmaTrain).
IMI is a joint undertaking of the European Commission and European Federation of Pharmaceutical Industries and Associations. PharmaTrain is the European platform for postgraduate training in Medicines Development and fosters the training needs and quality for all professionals in this field. The Centre of Excellence award is confirmation of King’s position at the forefront of pharmaceutical medicine education and training and makes King’s the preferred provider of pharmaceutical medicine training for the pharmaceutical industry including AstraZeneca, GlaxoSmithKline Novartis and Sanofi.
King’s School of Biomedical Sciences launched its suite of master’s level programmes and short courses in pharmaceutical medicine in 2010. The courses have been designed to cover the whole drug development process, including 3 Masters programmes which have been mapped out in order to cater for the different career opportunities within the specialty (Clinical Pharmacology, Drug Development Science and Translational Medicine). Several of the courses are accredited by the Faculty of Pharmaceutical Medicine for their pharmaceutical medicine specialist training programme and Certificate in Clinical Pharmacology.
Professor Roger Morris, Head of the School of Biomedical Sciences says: ‘There is a real need across Europe, and indeed globally, for modern training of industry and clinical professionals in medicines development that meets the highest academic and indusry standards. This award of Centre of Excellence status by PharmaTrain confirms our success in doing just that’.
Professor Brian Gennery, programme leader adds: 'This recognition is due to the high quality of teaching provided by the academic staff at King's supported by guest lecturers from the regulatory authorities and the pharmaceutical industry and will boost the numbers of students we can attract onto our programmes.'
Further information: